Zoledronic acid (Zometa®) enhances the cytotoxic effect of gemcitabine and fluvastatin: In vitro isobologram studies with conventional and nonconventional cytotoxic agents

Oncology

Volumn 70, Issue 2, 2006, Pages 147-153

  Budman, Daniel R ^a   Calabro, Anthony ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Fluvastatin; Gemcitabine; Synergy; Zoledronic acid

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DNA FRAGMENT; DOCETAXEL; EPIRUBICIN; FLOXURIDINE; FLUINDOSTATIN; GEMCITABINE; HISTONE; IMATINIB; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ZOLEDRONIC ACID;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; COLORIMETRY; CYTOTOXICITY; DNA FRAGMENTATION APOPTOSIS ASSAY; DRUG ADDITIVE EFFECT; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDIAN EFFECT ISOBOLOGRAM ANALYSIS; MONOLAYER CULTURE; MTT ASSAY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOPLASM; DEOXYCYTIDINE; DIPHOSPHONATES; DNA FRAGMENTATION; DRUG ANTAGONISM; DRUG SYNERGISM; EPIRUBICIN; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; IMIDAZOLES; INDOLES; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS;

EID: 33646783320     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093006     Document Type: Article

References (41)

1. Menschutkin N: Über die Einwirkung des Chlorazetyls auf phosphorige Säure. Ann Chem Pharm 1865;133:317-320.
2. Fleisch H: Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
3. Reszka AA, Rodan GA: Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003;5:65-74.
4. Berenson JR: New advances in the biology and treatment of myeloma bone disease. Semin Hematol 2001;38:15-20.
5. Body JJ: Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia 2001;6:477-485.
6. Coleman RE: Bisphosphonates for the prevention of bone metastases. Semin Oncol 2002;29:43-49.
7. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
8. Finley RS: Bisphosphonates in the treatment of bone metastases. Semin Oncol 2002;29:132-138.
9. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev 1999;25:293-299.
10. Berenson JR: Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002;29:12-18.
11. Neville-Webbe H, Coleman RE: The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia. Palliat Med 2003;17:539-553.
12. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-1476.
13. Mundy GR: Bisphosphonates as anticancer drugs. Expert Opin Investig Drugs 1999;8:2009-2015.
14. Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658.
15. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by amino-bisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-140.
16. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-1476.
17. Senaratne SG, Mansi JL, Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane (correction of impairs membrane) localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-1486.
18. Russo P, Loprevite M, Cesario A, Ardizzoni A: Farnesylated proteins as anticancer drug targets: from laboratory to the clinic. Curr Med Chem Anti-Cane Agents 2004;4:123-138.
19. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A: Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003;26:S92-S97.
20. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609-641.
21. Budman DR, Calabro A: In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 2002;74:41-46.
22. Budman DR, Calabro A, Kreis W: Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13:1011-1016.
23. Budman DR, Calabro A, Wang LG, Liu XM, Stiel L, Adams LM, Kreis W: Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000;18:695-701.
24. Budman DR, Calabro A: Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. Anticancer Drugs 2004;15:877-881.
25. Budman DR, Calabro A, Kreis W: In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? Leukemia 2001;15:1517-1520.
26. Budman DR, Calabro A, Kreis W: In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs 1998;9:697-702.
27. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
28. Kreis W, Budman DR, Calabro A: Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79:196-202.
29. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY: Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004;96:1769-1780.
30. Greco W, Bravo G, Parsons J: The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-385.
31. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1236.
32. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468.
33. Green JR: Antitumor effects of bisphosphonates. Cancer 2003;97:840-847.
34. Clezardin P: The antitumor potential of bisphosphonates. Semin Oncol 2002;29:33-42.
35. Zhang P, Lun M, Siegelmann-Danieli N, Blasick T, Brown R: Pamidronate resistance and associated low Ras levels in breast cancer cells: a role for combinatorial therapy. Ann Clin Lab Sci 2004;34:263-270.
36. Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y: Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 2004;1689:267-272.
37. Wang HR, Li JJ, Huang CX, Jiang H: Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60.
38. Fenton JW 2nd, Jeske WP; Catalfamo JL, Brezniak DV, Moon DG, Shen GX: Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc) 2002;67:85-91.
39. Mantha A, Hanson J, Goss G, Lagarde A, Lorimer I, Dimitroulakos J: Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005;11:2398-2407.
40. Vogt U, Bielawski KP, Bosse U, Schlotter CM: Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004;12:1109-1114.
41. Linn J, Duggan D, Chen I, Ellsworth R: Physiological disposition of alendronate, a potent antiosteolytic bisphosphonate in laboratory animals. Drug Metab Dispos 1991;19:926-932.